Brief: Ocuphire Pharma Publishes Full Phase 3 Results Of Phentolamine Ophthalmic Solution 0.75%

Opus Genetics

30/09/2024 13:27

Sept 30 (Reuters) - Ocuphire Pharma Inc  OCUP.O :
    * OCUPHIRE PHARMA ANNOUNCES PUBLICATION OF FULL PHASE 3
RESULTS OF
PHENTOLAMINE OPHTHALMIC SOLUTION 0.75% FOR
PHARMACOLOGICALLY-INDUCED MYDRIASIS IN OPHTHALMOLOGY
    * OCUPHIRE PHARMA INC: PHENTOLAMINE OPHTHALMIC SOLUTION
0.75%
EXHIBITED A FAVORABLE SAFETY PROFILE
    * OCUPHIRE PHARMA INC:  VEGA-3 PHASE 3 CLINICAL TRIAL
TOP-LINE
DATA ARE EXPECTED IN FIRST HALF OF 2025
    * OCUPHIRE PHARMA INC:  LYNX-2 PHASE 3 TRIAL TOP-LINE DATA
ARE
EXPECTED IN Q1 OF 2025.

Source text for Eikon:  urn:newsml:reuters.com:*:nGNXMLWXd
Further company coverage:  OCUP.O 

 ((Reuters.Briefs@thomsonreuters.com;))